Novel EGFR-targeted agents, such as gefitinib and erlotinib, may contribute an additional risk to the development of ILD, albeit via a pharmacological effect through the EGFR rather than directly as a result of biotransformation or chemical injury. The gene discussed is EGFR; the disease is interstitial lung disease.